Krebs: Mikronährstoffe in der onkologischen Intervention

Uwe Gröber; Peter Holzhauer; Irenäus Adamietz

doi:10.1055/s-0043-113077

Zeitschrift für Orthomolekulare Medizin, Inhaltsverzeichnis

Zeitschrift für Orthomolekulare Medizin 2017; 15(02): 7-18
DOI: 10.1055/s-0043-113077

Wissen

Karl F. Haug Verlag in Georg Thieme Verlag KG Stuttgart – New York

Krebs: Mikronährstoffe in der onkologischen Intervention

Uwe Gröber

,

Peter Holzhauer

,

Irenäus Adamietz

Abstract

Summary

Aktuelle Studien weisen darauf hin, dass der labordiagnostisch validierte und therapieangepasste Einsatz von Mikronährstoffen ein wichtiger Baustein supportiver und komplementäronkologischer Therapiekonzepte ist. Die optimale Versorgung mit Nahrungsenergie sowie antientzündlichen und immunstabilisierenden Mikronährstoffen wie Selen, L-Carnitin, Vitamin C und D steigert das Ansprechen auf antineoplastische Therapien und verringert die Nebenwirkungsrate. Lebensqualität und Prognose der Patienten können verbessert werden.

Keywords

Krebs - Mikronährstoffe - Malnutrition - Supportivtherapie - Magnesium - Vitamin D - Bisphosphonate - Selen - L-Carnitin - Vitamin C

Volltext

Referenzen

Literatur
1 Bray F, Jemal A, Grey N. et al. Global cancer transitions according to the Human Development Index (2008–2030): A population-based study. Lancet Oncol 2012; 13: 790-801
2 American Cancer Society Global Cancer: Facts and Figures. 3. Aufl. New York: American Cancer Society; 2015
3 Gröber U. Antioxidants and other micronutrients in complementary oncology. Breast Care 2009; 4 (01) 13-20
4 Ströhle A, Zänker K, Hahn A. Nutrition in oncology: the case of micronutrients. Oncol Rep 2010; 24 (04) 815-828
5 Gröber U, Holzhauer P, Kisters K. et al. Micronutrients in Oncological Intervention. Nutrients 2016; 8 (03) 163
6 Gröber U, Hübner J, Holzhauer P, Kleeberg UR. Antioxidanzien und andere Mikronährstoffe in der komplementären Onkologie. Onkologe 2010; 16: 73-79
7 Micke O, Bruns F, Glatzel M. et al. Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology. European Journal of Integrative Medicine 2009; 1: 22-30
8 D’Andrea G. Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin 2005; 55 (05) 319-321
9 Block KI. et al. Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. Cancer Treat Rev 2007; 33 (05) 407-418
10 Block KI. et al. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 2008; 123 (06) 1227-1239
11 Mücke R, Schomburg L, Büntzel J. et al. Komplementärer Seleneinsatz in der Onkologie. Der Onkologe, 2010; 16: 181-186
12 Gröber U. Arzneimittel und Mikronährstoffe. 3. Aufl. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2014
13 Tong H, Isenring E, Yates P. The prevalence of nutrition impact symptoms and their relationship to quality of life and clinical outcomes in medical oncology patients. Support Care Cancer 2009; 17 (01) 83-90
14 Bozzetti F. SCRINIO Working Group Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients. Support Care Cancer 2009; 17 (03) 279-284
15 Holzhauer P, Gröber U. Titel Der Gynäkologe 2016; Volume: Seitenzahl
16 Fakih M. Anti-EGFR monoclonal antibody-induced hypomagnesaemia. Lancet Oncol 2007; 8 (05) 366-367
17 Vickers MM, Karapetis CS, Tu D. et al. Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Ann Oncol. 2013; 24 (04) 953-960
18 Knijn N, Tol J, Koopman M. et al. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer 2011; 47 (03) 369-374
19 Chen P, Wang L, Li H. et al. Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis. Oncol Lett 2013; 5 (06) 1915-1920
20 McDonnell SL, Baggerly C, French CB. et al. Serum 25-Hydroxyvitamin D Concentrations ≥40 ng/ml Are Associated with > 65 % Lower Cancer Risk: Pooled Analysis of Randomized Trial and Prospective Cohort Study. PLoS One 2016; 11 (04) e0152441
21 Gröber U, Kisters K. Influence of drugs on vitamin D and calcium metabolism. Dermatoendocrinol 2012; 4 (02) 158-166
22 Gröber U, Spitz J, Reichrath J. et al. Vitamin D: Update 2013: From rickets prophylaxis to general preventive healthcare. Dermatoendocrinol 2013; 5 (03) 331-347
23 Fink M. Vitamin D deficiency is a cofactor of chemotherapy-induced mucocutaneous toxicity and dysgeusia. J Clin Oncol 2011; 29 (04) e81-e82
24 Prieto-Alhambra D, Javaid MK, Servitja S. et al. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospectiv cohort study. Breast Cancer Res Treat 2011; 125 (03) 869-878
25 Khan QJ, Reddy PS, Kimler BF. et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010; 119 (01) 111-118
26 Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med 2010; 363 (21) 2027-2035
27 Carmel AS, Shieh A, Bang H, Bockman RS. The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥ 33 ng/ml. Osteoporos Int 2012; 23 (10) 2479-2487
28 Berruti A, Cook R, Saad F. et al. Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. Oncologist 2012; 17 (05) 645-652
29 Bedogni A, Saia G, Bettini G. et al. Osteomalacia: the missing link in the pathogenesis of bisphosphonate-related osteonecrosis of the jaws?. Oncologist 2012; 17 (08) 1114-1119
30 Bergman P, Sperneder S, Höijer J. et al. Low vitamin d levels are associated with higher opioid dose in palliative cancer patients – results from an observational study in sweden. PLoS One 2015; 10 (05) e0128223
31 Dev R, Del Fabbro E, Schwartz GG. et al. Preliminary report: vitamin D deficiency in advanced cancer patients with symptoms of fatigue or anorexia. Oncologist 2011; 16 (11) 1637-1641
32 Khan QJ, Reddy PS, Kimler BF. et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010; 119 (01) 111-118
33 Bittenbring JT, Neumann F, Altmann B. et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. J Clin Oncol 2014; 32 (29) 3242-3248
34 Gröber U, Holick MF. Vitamin D: Die Heilkraft des Sonnenvitamins. 3., vollst. überarb. und erweiterte Aufl. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2015
35 Gröber U, Holzhauer P, Kisters K. Besser durch die Krebstherapie. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2014
36 Bellinger F P, Raman AV, Reeves MA, Berry MJ. Regulation and function of selenoproteins in human disease. Biochem J 2009; 422: 11-22
37 Wallenberg M, Misra S, Wasik AM. et al. Selenium induces a multi-targeted cell death process in addition to ROS formation. J. Cell Mol Med 2014; 18: 671-684
38 Wallenberg M, Misra S, Björnstedt M. Selenium cytotoxicity in cancer. Basic Clin Pharmacol Toxicol 2014; 114: 377-386
39 Dennert G, Zwahlen M, Brinkman M. et al. Selenium for preventing cancer. Cochrane Database Syst Rev 2011; (05) CD005195 doi: 10.1002/14651858.CD005195
40 Vinceti M, Dennert G, Crespi CM. et al. Selenium for preventing cancer. Cochrane Database Syst Rev. 2014; (03) CD005195 doi: 10.1002/14651858.CD005195.pub3
41 Brodin O, Eksborg S, Wallenberg M. et al. Pharmacokinetics and toxicity of sodium selenite in the treatment of patients with carcinoma in a phase I clinical trial: The SECAR Study. Nutrients 2015; 7: 4978-4994
42 Son H, Lee SM, Yoon RG. et al. Effect of selenium supplementation for protection of salivary glands from iodine-131 radiation damage in patients with differentiated thyroid cancer. Hell J Nucl Med 2017; 20 (01) 62-70
43 Khasabova IA. Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. J Neurosci 2012; 32 (20) 7091-7101
44 Visovsky C. et al. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin JOncol Nurs 2007; 11 (06) 901-913
45 Sun Y. et al. A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine ALC) in treatment of chemotherapy-induced peripheral neuropathy (CPIN). J Clin Oncol 2012; 30: abstr 9017 (symptom management/supportivecare/palliativecare)
46 Drisko JA, Chapman J, Hunter VJ. The use of antioxidants with firstline chemotherapy in two cases of ovarian cancer. J Am Coll Nutr 2003; 22: 118-123
47 Drisko J A, Chapman J, Hunter VJ. The use of antioxidant therapies during chemotherapy. Gynecol Oncol 2003; 88: 434-439
48 Vollbracht C, Schneider B, Leendert V. et al. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: Results of a retrospective, multicentre, epidemiological cohort study in Germany. Vivo 2011; 25: 983-990
49 Welsh J L, Wagner B A, van’t Erve. et al. Pharmacological ascorbate with gemcitabine for the control of metastastic and node-positive pancreatic cancer (PACMAN): Results from a phase I clinical trial. Cancer Chemother Pharmacol 2013; 71: 765-775
50 Monti DA, Mitchell E, Bazzan AJ. et al. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS ONE 2012; 7: e29794
51 Seo MS, Kim JK, Shim JY. High-dose vitamin C promotes regression of multiple pulmonary metastases originating from hepatocellular carcinoma. Yonsei Med J 2015; 56: 1449-1452
52 PDQ Cancer Complementary and Alternative Medicine Editorial Board High-Dose Vitamin C (PDQ): Health Professional Version. PDQ Cancer Information Summaries; National Cancer Institute; Bethesda, MD, USA: 2002–2015